Fig 1: CdtVEGF isolation. (A) Chromatographic profile of crude C. d. terrificus venom fractionation on C18 semipreparative column. The red dotted line represents the gradient of solution B (%). (B) ELISA assay using anti-VEGF-F of 30 fractions from C.d.terrificus fractionation. Each fraction was incubated with commercial anti-VEGF-F and absorbance was measured at 490 nm. Data are presented as mean ± SEM analyzed by one-way ANOVA and Tukey’s multiple comparison test (quadruplicate assay). *** p < 0.0001 when compared to its negative control. PC(+): wells coated with commercial rVEGF (AR31064PU-L, OriGene Technologies); SV: C. d. terrificus venom incubated with commercial anti-VEGF-F. (C) Fraction 19 applied on anion–ion exchange column. (D) CdtVEGF applied on heparin affinity column. The red dotted lines represent buffer B and/or solution B (%) gradients. An amount of 15% SDS-PAGE of fractions Q19-2 and Q19-3 under reduced (E) and nonreduced (F) conditions, stained with Coomassie Brilliant Blue G-250. MW: molecular weight marker (97.0–14.4 kDa).